About US
Contact us
-
Pfizer CEO psychs up investors for a rebate-free world under TrumpWhat would a world with no drug rebates look like? Pfizer’s Ian Read is already imagining it. “I would believe we're going to go to a marketplace where we don't have rebates,” he said Tuesday on Pf2018/8/2
-
Thanks to Genzyme—and no thanks to vaccines or diabetes—Sanofi is treading waterAs much as Sanofi has struggled with diabetes and generic drugs the past few years, it could typically count on vaccines and Genzyme to come to the rescue. This quarter, Genzyme played its usual lif2018/8/1
-
Indivior's new antipsychotic wins FDA nod, but Suboxone patent fight could delay its launchJust as Indivior stalledDr. Reddy’s rollout of a generic to its top-selling drug, Suboxone Film, the launch of a new drug of Indivior’s own might become collateral damage of the patent fight and the2018/7/31
-
The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 salesMerck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival Opdivo. For the se2018/7/30
-
Allergan CEO pooh-poohs investor sniping amid Q2 beat, but analysts aren't so sureThe critics moaning that Allergan’s plan to sell off its women’s health and infectious disease businesses doesn’t go far enough? The activist investors demanding CEO Brent Saunders give up the board2018/7/27
-
Forget a consumer spinoff. GlaxoSmithKline is plotting a $525M cost-cutting drive insteadForget the speculation you’ve heard over the past few days: GlaxoSmithKline is sticking with its three-unit structure, CEO Emma Walmsley told investors Wednesday. And in fact, it’s so committed to t2018/7/26
-
Pfizer building $465M sterile injectables plant at its Michigan sitePfizer has committed to building a massive, $465 million sterile manufacturing plant at its site in Michigan that is expected to add 450 new jobs by the time it is fully operational. Pfizer saidon2018/7/25
-
FDA chief Gottlieb blames drugmakers for ‘anemic’ biosimilar marketThe FDA has so far approved 11 biosimilars, drugs that should be saving patients billions of dollars. But so far, only three of the 11have made it to the market in the U.S., a fact FDA Commissioner2018/7/20
-
Johnson & Johnson softens FDA's Invokana blow with positive kidney resultsJohnson & Johnson has been waiting for its chance to tout Invokana’s cardiovascular benefits for diabetes patients, but thanks to an FDA delay, that won't be happening anytime soon. In the meant2018/7/18
-
Vertex says it's glad England made another offer for CF drugs, but it'll have to do betterVertex CEO Jeffrey Leiden's move earlier this month to pressure England's prime minister Theresa May on drug prices seems to have set some wheels in motion. After negotiations seemingly broke down b2018/7/18